Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
New Insights Into Non-Alcoholic Fatty Liver Diseases
share announcement

New Insights Into Non-Alcoholic Fatty Liver Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 826

Special Issue Editors

Dr. Hazem Ayesh

E-Mail Website
Guest Editor
Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN, USA
Interests: NAFLD; non-alcoholic fatty liver disease; metabolic pathways; molecular mechanisms; genetic polymorphisms; population disparities; risk stratification; clinical challenges; nutritional interventions; triglyceride glucose index
Dr. Robert Schierwagen

E-Mail Website
Guest Editor
Department of Internal Medicine B, University of Münster, 48149 Münster, Germany
Interests: non-alcoholic fatty liver disease; portal hypertension; janus-kinase 2; mas receptor

Special Issue Information

Dear Colleagues,

Non-alcoholic fatty liver disease (NAFLD) poses a significant global health challenge, affecting patients across all age groups, from children to middle-aged and older adults, and is linked to diabetes and cardiovascular diseases. Clinical challenges, including underdiagnosis and the imperative for precise risk stratification, highlight the urgency of comprehending molecular mechanisms, population disparities, and metabolic pathways in the early stages of pathogenesis. This Special Issue delves into essential aspects, focusing on metabolic pathways influencing fatty liver, deciphering genetic contributions to pathogenesis, and exploring population-specific differences. Additionally, we illuminate the crucial role of various metabolic pathways in NAFLD pathogenesis, aiming to deepen our understanding of treatment options. Insights into nutritional interventions, the triglyceride glucose index, and genetic polymorphisms emerge as pivotal elements for addressing NAFLD progression, emphasizing the need for tailored nutritional programs and targeted pharmacological interventions.

Dr. Hazem Ayesh
Dr. Robert Schierwagen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • NAFLD
  • non-alcoholic fatty liver disease
  • metabolic pathways
  • molecular mechanisms
  • genetic polymorphisms
  • population disparities
  • risk stratification
  • clinical challenges
  • nutritional interventions
  • triglyceride glucose index

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

16 pages, 1970 KiB  
Systematic Review
Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials
by Hazem Ayesh, Azizullah Beran, Sajida Suhail, Suhail Ayesh and Kevin Niswender
Biomedicines 2024, 12(10), 2328; https://doi.org/10.3390/biomedicines12102328 - 14 Oct 2024
Viewed by 662
Abstract
Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction Associated Steatohepatitis (MASH) are linked to obesity, type 2 diabetes, and metabolic syndrome, increasing liver-related morbidity and cardiovascular risk. Recent therapies, including Resmetirom, FGF21 analogs, and GLP-1 agonists, have shown promise. This network meta-analysis [...] Read more.
Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction Associated Steatohepatitis (MASH) are linked to obesity, type 2 diabetes, and metabolic syndrome, increasing liver-related morbidity and cardiovascular risk. Recent therapies, including Resmetirom, FGF21 analogs, and GLP-1 agonists, have shown promise. This network meta-analysis evaluates their comparative efficacy and safety. Methods: A literature search was conducted across PubMed, Scopus, Web of Science, and Cochrane Library. Included clinical trials addressed MASLD or MASH with Resmetirom, FGF21 analogs, or GLP-1 agonists. Statistical analyses used a random-effects model, calculating mean differences (MD) and relative risks (RR), with heterogeneity assessed using τ2, I2, and Q statistics. Results: MASH resolution was significantly higher for FGF21 (RR 4.84, 95% CI: 2.59 to 9.03), Resmetirom showed the most significant reduction in MRI-PDFF (MD −18.41, 95% CI: −23.60 to −13.22) and >30% fat reduction (RR 3.56, 95% CI: 2.41 to 5.26). Resmetirom significantly reduced ALT (MD −15.71, 95% CI: −23.30 to −8.13), AST (MD −12.28, 95% CI: −21.07 to −3.49), and GGT (MD −19.56, 95% CI: −34.68 to −4.44). FGF21 and GLP-1 also reduced these markers. Adverse events were significantly higher with Resmetirom (RR 1.47, 95% CI: 1.24 to 1.74), while GLP-1 and FGF21 showed non-significant trends towards increased risk. Conclusions: Resmetirom and FGF21 show promise in treating MASLD and MASH, with Resmetirom particularly effective in reducing liver fat and improving liver enzymes. GLP-1 agonists also show benefits but to a lesser extent. Further long-term studies are needed to validate these findings and assess cost-effectiveness. Full article
(This article belongs to the Special Issue New Insights Into Non-Alcoholic Fatty Liver Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop